Urologix Shakes Off Reimbursement Woes; Stock Is Up Nearly 80% In July
This article was originally published in The Gray Sheet
Executive Summary
Urologix' announcement that its Targis microwave system likely will be reimbursed on par with other minimally invasive therapies for benign prostatic hyperplasia under the Health Care Financing Administration's physician fee schedule signaled that the firm's payment problems may finally be coming to an end. The issue ended July up 78.5%.
You may also be interested in...
BPH Treatment Devices To Be Reimbursed By HCFA At Approximately $1,875
EDAP expects that the lower cost of its Prostatron microwave-based system for treating benign prostatic hyperplasia will make the product more attractive than competing devices now that therapy has been assigned an ambulatory payment classification (APC) code with a set reimbursement level.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.